Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Net Margin (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Net Margin for 6 consecutive years, with 1689.24% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 486362.0% year-over-year to 1689.24%, compared with a TTM value of 279.32% through Sep 2025, up 121302.0%, and an annual FY2024 reading of 1442.31%, changed N/A over the prior year.
  • Net Margin was 1689.24% for Q3 2025 at X4 Pharmaceuticals, down from 1304.66% in the prior quarter.
  • Across five years, Net Margin topped out at 16133.75% in Q2 2024 and bottomed at 6552.86% in Q3 2024.
  • Average Net Margin over 4 years is 1717.39%, with a median of 2157.27% recorded in 2022.
  • The sharpest move saw Net Margin surged 1128079bps in 2024, then tumbled -1743841bps in 2025.
  • Year by year, Net Margin stood at 2544.06% in 2022, then surged by 91bps to 4852.96% in 2023, then tumbled by -155bps to 2654.73% in 2024, then skyrocketed by 36bps to 1689.24% in 2025.
  • Business Quant data shows Net Margin for XFOR at 1689.24% in Q3 2025, 1304.66% in Q2 2025, and 0.98% in Q1 2025.